lupus.bmj3d
LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
3 Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA 4 Division of Rheumatology, Allergy and Immunology, University of California San ...
lupus.bmj3d
Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...
lupus.bmj4d
Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
lupus.bmj4d
305 Using ACR-component based unsupervised clustering with Olink proteomics to resolve SLE heterogeneity
Background The high heterogeneity in systemic lupus erythematosus (SLE) implies that differential treatment may be required for different patient strata, hence there is an increased need of accurate ...
lupus.bmj5d
Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE
Objective Patients with SLE have an increased risk of atherosclerosis (ATH) that is not adequately explained by traditional risk factors. We previously described the Predictors of Risk for Elevated ...